From: The clinical potential of gene editing as a tool to engineer cell-based therapeutics
Disease | Trial name | Phase | Cell type edited | Target patients | Status | Sponsor | Countries | CT number |
---|---|---|---|---|---|---|---|---|
Cancer | Study of UCART19 in pediatric patients with relapsed/refractory B acute lymphoblastic leukemia (PALL) | I | Allogeneic T-cells | Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia (B-ALL) | Recruiting—posted June 21, 2016; updated October 25, 2019 | Institut de recherches internationales servier | USA, UK, Belgium, France, Spain | NCT02808442 |
Dose escalation study of UCART19 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (CALM) | I | Allogeneic T-cells | Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia (B-ALL) | Recruiting—posted April 21, 2016; updated October 25, 2019 | Institut de Recherches Internationales Servier | USA, UK, France, Japan | NCT02746952 | |
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19/ALLO-501 | I | Allogeneic T-cells | Patients with advanced lymphoid malignancies dosed with UCART19/ALLO-501 (long-term safety evaluation) | Enrolling by invitation—posted April 12, 2016; updated January 7, 2020 | Institut de Recherches Internationales Servier | USA, Belgium, France, Spain, UK | NCT02735083 | |
Safety and efficacy of ALLO-501 anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory large B cell or follicular lymphoma (ALPHA) | I/II | Allogeneic T-cells | Relapsed or refractory CD19 positive large B-cell lymphoma or follicular lymphoma patients | Recruiting—posted May 6, 2019; updated January 13, 2020 | Allogene Therapeutics | USA | NCT03939026 | |
Study evaluating safety and efficacy of UCART123 in patients with acute myeloid leukemia (AMELI-01) | I | Allogeneic T-cells | Patients with CD123 expressing relapsed/refractory AML patients, and in poor-prognosis, newly diagnosed AML patients in the European LeukemiaNet (ELN) adverse genetic risk group | Recruiting—posted June 16, 2017; updated December 6, 2019 | Cellectis S.A. | USA | NCT03190278 | |
Safety and efficacy of ALLO-715 BCMA allogenic CAR T cells in in adults with relapsed or refractory multiple myeloma (UNIVERSAL) (UNIVERSAL) | I | Allogeneic T-cells | Patients with relapsed or refractory multiple myeloma (MM) refractory to at least three prior lines of MM therapy | Recruting—posted September 18, 2019; updated December 12, 2019 | Allogene Therapeutics | USA | NCT04093596 | |
Phase I study of UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (BALLI-01) | I | Allogeneic T-cells | Patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukaemia (B-ALL) | Recruiting—posted November 4, 2019 | Cellectis S.A | USA | NCT04150497 | |
Study evaluating safety and efficacy of UCART targeting CS1 in patients with relapsed/refractory multiple myeloma (MELANI-01) | I | Allogeneic T-cells | Patients with relapsed or refractory multiple myeloma (MM) | Recruiting—posted October 29, 2019; updated November 27, 2019 | Cellectis S.A | USA | NCT04142619 |